Patent law won't marr India's industry

Novartis may be the only Big Pharma firm to pull the plug in India in the wake of the Glivec patent fight. You'll recall that an Indian court wouldn't grant Novartis protection for Glivec, citing laws that prohibit patenting drugs that offer only marginal improvements over existing products. Novartis then said it was canceling plans to invest hundreds of millions in the country.

Meanwhile, though, other pharmaceuticals companies are forging right ahead. India's talent pool and cost profile make it too attractive, analysts say. Plus, several companies are deeply entrenched in manufacturing and/or research partnerships with Indian companies such as Ranbaxy. 

- read the report on India from the Business-Standard

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?